At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 6-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Safety and Efficacy Study of the Potential Inhibitory Effects on the Hypothalamic-Pituitary-Adrenal Axis of Ciclesonide HFA Nasal Aerosol and Ciclesonide Aqueous Nasal Spray in Subjects 12 Years and Older With Perennial Allergic Rhinitis
In Brief
A Phase 3 clinical trial evaluating Ciclesonide HFA Nasal Aerosol 320 mcg, Ciclesonide HFA Nasal Aerosol 160 mcg, and 5 other interventions for Perennial Allergic Rhinitis. Completed, enrolled 310 participants across 6 sites.
Detailed Summary
To demonstrate the effects of ciclesonide applied as a nasal aerosol and ciclesonide aqueous (AQ) nasal spray on hypothalamic-pituitary-adrenal axis.
Study Details
Timeline
Interventions
Ciclesonide HFA Nasal Aerosol 320 μg once daily
Ciclesonide HFA Nasal Aerosol 160 μg once daily
HFA Nasal Aerosol placebo once daily
Ciclesonide Aqueous Nasal Spray 200 mcg once daily
AQ Nasal Spray Placebo once daily
Dexamethasone capsules 6 mg once daily
Placebo AQ plus Dexamethasone 6 mcg capsules once daily